Vice Director of the Pharmaceutical Supervision Bureau; two executives of pharmaceutical companies were arrested; the Medical Insurance Bureau notified the hospital's medication status

This week, Hainan's epidemic prevention and control situation is complicated and severe, and medical staff in many provinces and municipalities assisted Hainan. Sun Chunlan, deputy prime minister of the State Council, instructed that more resolute and decisive measures were taken to quickly improve, and various measures were urgently grasped the specifics and realized the society as soon as possible.

In terms of policy, the Ministry of Industry and Information Technology, the Medical Insurance Bureau, the Drug Administration, and the four departments of the Health and Health Commission jointly issued a notice to monitor the selection of varieties and production enterprises in 1236 shortage drugs and manufacturers, and 783 countries.

The Hubei Provincial Medical Insurance Bureau reported the completion of the agreed procurement of the national organizational drugs.

Officials with official departments were mobilized, and the official website of the Ministry of Human Resources and Social Security, Huang Guo served as the Deputy Director of the State Drug Administration. The position of deputy director of the State Drug Administration of Chen Shifei was removed.

On August 12, Ji Ya Holdings issued an announcement saying that the public security organs recently notified that the company's former chairman Sun Jun, former director and deputy general manager Wang Deheng had been approved by suspected duties.

Fosun Pharmaceutical disclosed the price of Azf's fixed table. Each bottle is 270 yuan, and it has been temporarily included in medical insurance. Azf is also included in the new type of coronary virus pneumonia diagnosis and treatment plan,

More hot spots are organized as follows:

Heavy policy

1. High -level instructions in Hainan's epidemic is urgent and extinguished as soon as possible

On August 13, Sun Chunlan, vice premier of the State Council, went to Hainan to investigate and guide the prevention and control of the epidemic.

Sun Chunlan emphasized that in accordance with the requirements of the ninth edition of the prevention and control plan, strengthen the province's resources and coordinating allocation, highlight the key points, concentrated strength, and compact responsibilities, take more resolute and decisive measures to quickly improve, and urgently grasp various measures and seize them carefully. Specifically, realize the clear society as soon as possible to ensure the health and safety of the masses and the order of normal production and living.

The Hainan epidemic is currently in a high -level fluctuation period, and the situation of prevention and control is complicated and severe. The country has coordinated 16,700 medical personnel and 1.97 million pipes/daily nucleic acid detection capabilities in 20 provinces, autonomous regions, and municipalities.

Sun Chunlan pointed out that in order to do a good job in the service guarantee of trapped passengers, and accelerate the progress, relevant provinces and cities shall not refuse or receive the limit.

2. The State Drug Administration ushered in the new deputy director

On August 10, the official website of the Ministry of Human Resources and Social Security, Huang Guo served as Deputy Director of the State Drug Administration. The position of deputy director of Chen Shifei's National Drug Administration is removed.

According to the information of the official website of the State Drug Administration, Huang Guo served as the deputy director of the Office of the State Food and Drug Administration in August 2011; since December 2013, he has been the deputy director of the General Office; Director of the Information Center (China Food and Drug Supervision Data Center); since June 2017, he has been the party secretary of the China Food and Drug Administration Data Center.

Chen Shifei, born in July 1962, is 60 years old. On September 29, 2018, he served as Deputy Director of the State Drug Administration.

3. The purchase volume of many hospitals does not meet the standard

On August 8th, the Hubei Provincial Medical Insurance Bureau reported the completion of the agreed purchase volume of the National Pharmaceutical Collection. After one year of the second and fourth batch, the completion rate was 116%and 134%; 80%of the task.

The accuracy and completion rate of the Tianyou Hospital of Wuhan University of Science and Technology and Hubei Provincial Traditional Chinese and Western Medicine Hospital ranked among the top in the province. Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan University People's Hospital, Hubei Provincial Maternal and Child Health Hospital, Hubei Province Third People's Hospital, Hubei Provincial Hospital of Traditional Chinese Medicine, and Wuhan University Zhongnan Hospital basically completed the overall agreed purchase volume.

However, some medical institutions did not complete the agreed purchase volume. China University of Science and Technology of Tongji Medical College, Hubei Cancer Hospital, Hubei Cancer Hospital, Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, the Central Theater General Hospital of the People's Liberation Army, and Hubei Rongjun Hospital have not completed the agreed procurement. Hubei Province's hospitals are not allowed and the amount is inadequate.

The Hubei Medical Insurance Bureau stated that the next step will be interviewed to these hospitals.

4. Shanghai clearly needs to learn Sanming's medical reform model

On August 9th, the Office of the Leading Group of Shanghai Deepening the Reform of the Pharmaceutical and Health System issued the "Work Plan on Promoting the Promotion of Fujian Sanming Experience to Deepen the Reform of the Pharmaceutical and Health System", requiring in -depth study, fully drawing on the experience of Sanming's medical reform, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical care, deepening medical treatment The reform of medical insurance and medicine has consolidated and improved the effectiveness of the city's comprehensive medical reform, and accelerated the high -quality development of health and health undertakings.

The "Plan" requires that the number of medicines for the collection of drugs by the end of 2022 will exceed 300, and the "14th Five -Year Plan" period is more than 500. In response to drugs and high -value consumables with large amounts and high procurement amounts outside of China Cai, and conducting high -value consumables, the market collection is carried out. The encouragement of the collection of collection is not included in the collection of centralized procurement in the form of a medical federation or voluntarily formed the procurement alliance. Shanghai also encourages social medical institutions to join the medical consortium.

5. The four departments focus on monitoring more than 2,000 medicines, involving thousands of pharmaceutical companies

On August 9, the Ministry of Industry and Information Technology, the State Health and Health Commission, the State Medical Insurance Bureau, and the four departments of the State Drug Administration jointly issued a notice that 1236 shortage drugs and production enterprises, 783 national organizations organized selection of varieties and production enterprises.

The Jianzhi Bureau sorted out and found that the short -term varieties monitored this time include China Resources Pharmaceutic Pharine hydrochloric acid dopamine injection, Beijing Saisheng's injection of urine excitement, Tianjin Jinyao Pharmaceutical sulfate injection, etc. Variety: Hoson's moxininicinininib, Ganli Pharmaceuticals, canopya insulin injection/preserved insulin injection/martial arts injection and insulin injection and other products. It is worth mentioning that not all Chinese -elected enterprises of the national varieties are monitored, and the varieties and enterprises monitoring in different provinces and cities are different. Ability is related.

Industry affairs

1. Azf fixed -chip pricing 270 yuan per bottle

On August 9th, according to the official website of the National Health and Health Commission, after research, Azf has been included in the "New Coronatte Virus Pneumonia Diagnosis and Treatment Plan (Ninth Edition)". The indication is used to treat ordinary new coronary virus Patients with pneumonia, 5mg each time, once a day, no more than 14 days for treatment. Azf was previously used for HIV patients.

On August 13, the Hainan Provincial Medical Insurance Bureau issued an announcement saying that Azf's fixed films will be temporarily included in the medical insurance fund payment scope since August 9. The person in charge of Fosun Pharmaceutical revealed to the media: The price of Azf's medical insurance network in various places is 270 yuan per bottle, and the price has a great advantage over the new crown drugs on the market.

2. Two executives of listed pharmaceutical companies are arrested

On August 12, Ji Ya Holdings issued an announcement saying that the public security organs recently notified that the company's former chairman Sun Jun, former director and deputy general manager Wang Deheng had been approved by suspected duties.

The "Announcement" pointed out that the current case is still under investigation of the public security organs. The company will fully cooperate with the public security organs' investigation of the above cases to recover the company's losses to the greatest efforts.

The Jianzhi Bureau was informed that Sun Jun and Wang Deheng had both resigned from the company on June 8, 2019, respectively on June 8, 2019, respectively. Ji Pharmaceutical Holdings did not disclose the details of the case in the announcement.

3. Johnson & Johnson announced the global babies with slippery stone powder

On August 11, Johnson & Johnson announced that it was discontinued in babies containing talcum powder in the world. According to reports, Johnson & Johnson is currently facing about 38,000 lawsuits, saying that its related products have caused cancer due to pollution of carcinogens.

In this regard, Johnson & Johnson reiterated in the statement of the day that independent scientific analysis over the past decades has proven that its talc powder products are safe, without asbestos, and will not cause cancer. As of now, Johnson & Johnson's plan has gradually transitioned to all corn starch as raw materials, and related products have begun to be sold in many countries.

4. Byte beating acquisition of the United States and China Yihe

According to the company's investigation data, the byte beating has increased its shareholding of the equity of the US -China Yihe Medical Management (Group) Co., Ltd., and according to media reports, the amount of mergers and acquisitions is about 10 billion yuan.

The United States and China are private medical institutions that provide obstetrics, gynecological, pediatrics, auxiliary reproductive, postpartum recovery, postpartum recreation, and medical beauty. Her founder was Hu Lan, who founded Meizhongyihe in 2006, and the first hospital settled in Beijing.

Wang Lei, vice president of Meizhongyi and Medical Group, said that after the byte beating control, the intervention of the hospital's operation level will not be much, "they only invest in." In the existing business territory of byte beating, there is no direct business related to obstetrics and gynecology. The Holdings of the Holdings of the United States and China also marked the expansion of the medical layout of byte beating.

New drug inventory

1. The new adaptation of the ADC "Shenyao" is approved by the FDA

On August 11, the FDA accelerated the newly approved ENHERTU (number DS-8201) for the first three and three common indications, which was used for patients with irregularity or metastatic HER2 mutant-positive adult non-small cell lung cancer patients that were previously treated with systematic treatment. This is the first drug approved by the FDA for HER2 mutant -positive non -small cell lung cancer. ENHERTU is an ADC therapy jointly developed by Astraikon and the first and third co -developed.

2. Zhongsheng Geno won the first certificate of the domestic HPV first sieve basics

On August 4, 2022, the "ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671 genethized testing kit (fluorescent PCR method) The medical device registration certificate issued by the State Drug Administration, which is the first certificate of radical departure of domestic cervical cancer HPV.

3. Baiji Shenzhou PD-1 liver cancer phase 3 clinical clinical ending

On August 9th, Baiji Shenzhou announced that the Ratchale301 study of the third phase of Baize Safety Ball reached the main end point. Among the non -removable hepatocytal carcinoma adult patients in the treatment of the front line Compared with the non -disadvantages of the total survival period. As of June 30, Baizean was approved for a total of nine adaptives.

#### Hainan epidemic#

- END -